Drugs / IX001 TCR-T injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06898385 | Mar 2025 → Mar 2027 expected | malignant pancreatic neoplasm | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IX001 TCR-T injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06898385 ↗ |
| Modality | Cell therapy | “IX001 TCR-T injection” NCT06898385 ↗ |
| Target | KRAS | “IX001 TCR-T injection targeted for KRAS mutation” NCT06898385 ↗ |